Navigation Links
Embolization a Nonsurgical Way to Treat Fibroids
Date:3/18/2008

It works even after other therapies have failed, but many women unaware of this option, experts say,,

TUESDAY, March 18 (HealthDay News) -- Uterine artery embolization is an effective, non-surgical therapy for fibroids, even after a woman has had other treatments such as focused ultrasound surgery, a new study says.

But another team of researchers reports that many American women are unaware of embolization as a treatment option.

The two studies were to be presented Tuesday at the Society of Interventional Radiology's annual meeting, in Washington, D.C.

"If you're suffering with symptomatic fibroids, you don't have to have surgery. Uterine artery embolization is an excellent option," said the author of one of the studies, Dr. John Lipman, director of interventional radiology at Emory-Adventist Hospital in Atlanta. "There are some women who are silent sufferers. They basically hemorrhage each month because they know they don't want a hysterectomy and they feel it's the only option. So, they just sit on the sidelines because they don't want the surgery."

Uterine artery embolization (UAE), which is sometimes called uterine fibroid embolization, cuts off the blood supply to fibroids by blocking the uterine arteries. The procedure is minimally invasive, doesn't require general anesthesia, and often allows women to return to normal daily activities within a week, instead of the six weeks or so needed for recovery from a hysterectomy.

The downside to this procedure is that it's not effective for everyone, and in rare cases, the fibroids may recur, according to the Society of Interventional Radiology (SIR).

Other treatment options -- such as hysterectomy (surgical removal of the uterus) and myomectomy (surgical removal of individual fibroids) -- are available, as is magnetic resonance-guided focused ultrasound. This technique is also known as focused ultrasound surgery (FUS) or ablati
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Terumo Launches the New AZUR(TM) Peripheral HydroCoil(R) Embolization System with Expanding Hydrogel Technology
2. Satisfaction After Fibroid Embolization Similar to Hysterectomy
3. Psychological intervention reduces postembolization pain
4. Few Women Hear About Uterine Fibroid Embolization Treatment Option Directly From Gynecologists
5. Study finds spine surgery yields greater benefits over nonsurgical treatments
6. Using coxibs and NSAIDs to treat osteoarthritis
7. New treatment effective in counteracting cocaine-induced symptoms
8. New treatment boosts muscle function in myasthenia gravis
9. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
10. Free distribution of insecticide-treated mosquito nets can save lives
11. Kenyan malaria success strengthens call for free insecticide-treated nets for all
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Embolization a Nonsurgical Way to Treat Fibroids
Embolization a Nonsurgical Way to Treat Fibroids
Breaking Medicine News(10 mins):Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Procter & Gamble Announces Appointment of Director 2Health News:Possible ovarian cancer treatment target identified 2Health News:Testosterone Gets Bad Rap: Study 2Health News:Testosterone Gets Bad Rap: Study 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 2Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 3Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 4Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 5Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 6Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 7Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 8Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 9Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 10Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 11Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 12Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 13Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 14Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 15Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 16Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 17Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 18Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 19Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 20Health News:Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries) 21
Breaking Medicine Technology:Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 2Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 3Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 4Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 5Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 6Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 7Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 8Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide 9Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 2Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 3Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 4Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 5Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 6Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 7Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective 8Members of National CHD Organization Unite for Little Hearts Celebration and Assemble for Picture of Hope 48154 1Members of National CHD Organization Unite for Little Hearts Celebration and Assemble for Picture of Hope 48154 2Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 1Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 2Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 3Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 4Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex 28Ferric Citrate 29 for the Treatment of Hyperphosphatemia in End Stage Re 12516 5Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 1Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 2Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 3Intarcia Therapeutics Inc Presents ITCA 650 Phase 1b Study Results as a Late Breaker at the American Diabetes Association 69th Scientific Sessions 12513 4